Here are the latest quarterly results of Torrent Pharma. For more details, see the Torrent Pharma financial fact sheet and Torrent Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.
No. of Mths Qtr. Ending |
3
Dec-18* |
3
Mar-19* |
3
Jun-19* |
3
Sep-19* |
3
Dec-19* |
3
Mar-20* |
3
Jun-20* |
3
Sep-20* |
8-Qtr Chart Click to enlarge |
|
---|---|---|---|---|---|---|---|---|---|---|
Net Sales | Rs m | 20,510 | 18,560 | 20,220 | 20,050 | 19,660 | 19,460 | 20,560 | 20,170 | |
Other income | Rs m | 30 | 170 | 200 | 340 | 530 | 150 | 40 | 60 | |
Turnover | Rs m | 20,540 | 18,730 | 20,420 | 20,390 | 20,190 | 19,610 | 20,600 | 20,230 | |
Expenses | Rs m | 14,900 | 13,830 | 14,810 | 14,640 | 14,260 | 13,980 | 13,950 | 13,820 | |
Gross profit | Rs m | 5,610 | 1,160 | 5,410 | 5,410 | 5,400 | 5,480 | 6,610 | 6,350 | |
Depreciation | Rs m | 1,560 | 1,600 | 1,600 | 1,630 | 1,630 | 1,680 | 1,610 | 1,650 | |
Interest | Rs m | 1,330 | 1,230 | 1,220 | 1,160 | 1,110 | 1,020 | 1,020 | 920 | |
Profit before tax | Rs m | 2,750 | -1,500 | 2,790 | 2,960 | 3,190 | 2,930 | 4,020 | 3,840 | |
Tax | Rs m | 290 | 20 | 630 | 520 | 680 | -210 | 810 | 740 | |
Profit after tax | Rs m | 2,460 | -1,520 | 2,160 | 2,440 | 2,510 | 3,140 | 3,210 | 3,100 | |
Gross profit margin | % | 27.4 | 6.3 | 26.8 | 27.0 | 27.5 | 28.2 | 32.1 | 31.5 | |
Effective tax rate | % | 10.5 | -1.3 | 22.6 | 17.6 | 21.3 | -7.2 | 20.1 | 19.3 | |
Net profit margin | % | 12.0 | -8.2 | 10.7 | 12.2 | 12.8 | 16.1 | 15.6 | 15.4 | |
Diluted EPS | Rs | 14.5 | -9.0 | 12.8 | 14.4 | 14.8 | 18.6 | 19.0 | 18.3 | |
Diluted EPS (TTM) | Rs | 48.2 | 25.8 | 28.9 | 32.7 | 33.0 | 60.6 | 66.8 | 70.7 | |
![]() |
Read: Torrent Pharma 2QFY21 Result Performance Review
More Pharmaceuticals Company Quarterly Results: LUPIN INDRAPRASTHA MEDICAL DIVIS LABORATORIES PANACEA BIOTECH INDOCO REMEDIES
Compare TORRENT PHARMA With: LUPIN INDRAPRASTHA MEDICAL DIVIS LABORATORIES PANACEA BIOTECH INDOCO REMEDIES
Compare TORRENT PHARMA With: ACTAVIS (US) MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Indian share markets witnessed huge selling during closing hours on Friday and ended lower.
For the quarter ended September 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 27.0% YoY). Sales on the other hand came in at Rs 20 bn (up 0.6% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.
For the quarter ended June 2020, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 48.6% YoY). Sales on the other hand came in at Rs 21 bn (up 1.7% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.
More Views on NewsLast time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
In this video, I'll show you how to get started on the path to daily trading profits.
An Indian company founded three decades ago in a garage caught my attention...
In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.
More